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Abstract
Background: Regular examination and early treatment of diabetic retinopathy can prevent visual
loss. The aim of the study was to describe the care of vision and ocular health in people with
diabetes in Norway.
Methods:  A cross-sectional questionnaire survey of a random sample (n = 1,887) of the
Norwegian Diabetic Associations' (NDA) members was carried out in 2005. Questions were asked
about care of vision and ocular health, history of ocular disease and visual symptoms, general
medical history and diabetes management. The study was approved by the Regional Committee for
Medical Research Ethics.
Results: The response rate was 74%. Forty-four questionnaires with incomplete data regarding
gender, age or type of diabetes were excluded, leaving 1352 cases (52% females) for analysis. 451
(33%) had type 1 and 901 (67%) had type 2 diabetes, the mean duration of diabetes was
respectively, 22 (sd ± 14) and 10 (sd ± 9) years. In all 1,052 (78%) had their eyes examined
according to guidelines and 1,169 (87%) confirmed to have received information about regular eye
examinations. One in two recalled to have received such information from their general
practitioner. To have received information about the importance of eye examinations (PR 3.1, 95%
CI 2.4 to 4.0), and diabetes duration > 10 years (PR 1.2, 95% CI 1.2 to 1.3), were independently
associated with reporting regular eye examinations. A history of diabetic retinopathy was reported
by 178 (13%) responders, of which 101 (57%) reported a history of laser treatment. Responders
who had regular eye examinations reported more frequently a history of diabetic retinopathy (19%
vs. 5%, p < 0.001). The frequency of retinopathy was significantly higher in responders with
reported HbA1c values above treatment target (23% vs. 13%, p = 0.001). However, in responders
who were not regularly examined, there was no difference in reported frequency of retinopathy
with regard to HbA1c level.
Conclusion: Eight out of ten diabetic members of the NDA had their eyes examined according to
current guidelines and the majority was well informed about the risk of vision loss due to diabetes.
The results indicate that the reported history of diabetic retinopathy likely underestimates the
prevalence of retinopathy.
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Background
In Western societies, diabetic retinopathy is one of the
leading causes of visual impairment and blindness in the
working age group [1-3]. The prevalence of diabetic retin-
opathy in Norway is sparsely described in the literature
[4,5]. It is estimated that 90–120,000 Norwegians have
known diabetes and that probably just as many have
undiagnosed diabetes [6]. Most diabetic patients will
develop some degree of retinopathy. Studies indicate that
between 6% and 30% will develop sight threatening retin-
opathy during the course of their illness [7-14]. In West-
ern Europe, diabetic retinopathy accounts for 4.7–13.3%
of the blind and partial sight registrations [3,15-17]. Reg-
ular examination of ocular health and early treatment of
diabetic retinopathy can prevent most cases of visual loss
[18-22], and ophthalmologic screening of patients with
diabetes is more cost-effective than many other health
interventions for detecting and treating disease [21,23].
The Norwegian College of General Practitioners has pub-
lished guidelines for examination of ocular health in
patients with diabetes, first issued in 1988 [24]. Table 1
shows the Norwegian practice guidelines compared to
practice guidelines in the United Kingdom, USA and Aus-
tralia. In 1996 only 53% of diabetic patients seen in gen-
eral practice were managed according to these guidelines
[25,26].
The aim of this study was to describe and analyse the care
of vision and ocular health among people with diabetes in
Norway. Secondly, we wanted to explore their sources of
information regarding ocular care. Finally we liked to
assess the reported care in relation to established practice
guidelines and to identify features associated with good
practice.
Methods
The study had a cross-sectional design. A random sample
of persons with diabetes, drawn from the member list of
the Norwegian Diabetes Association (NDA), was invited
to participate in a questionnaire survey. At the time of the
study, NDA was the only national registry of adults with
diabetes. NDA is a voluntary, independent organization
with the objective of serving people with diabetes and
others who have an interest in diabetes. In 2005 NDA had
35,058 members, including mainly people with diabetes,
some of their relatives (about 900), and around 3,000
health care professionals. The type of diabetes was not
recorded in the NDA membership registry. A random
sample comprising about 6% of NDA members 18 years
and older was drawn by computer from the NDA mem-
bership registry. They were subsequently sent a postal
questionnaire in October-December 2005. Non-diabetics,
deceased members and members with unknown address
or living abroad were excluded, leaving an eligible sample
of 1,887. Information about the study, the voluntary
nature of participation, confidentiality and study
approval were given on the front page of the question-
naire and the return of a completed questionnaire was
regarded as written consent. Reminders were sent once to
all participants. The questionnaire had been assessed in a
pilot survey. This pilot survey led to the inclusion of a
question regarding source of information about the
importance of regular eye examinations. The question-
naire included questions about care of vision and ocular
health, history of ocular disease and visual symptoms, as
well as details about type of diabetes, year of diagnosis,
treatment, blood glucose stability, most recently recorded
HbA1c and blood pressure, antihypertensive and choles-
terol lowering medication, and current and previous
Table 1: Practice guidelines for HbA1c treatment target and management of ocular health in patients with diabetes.
Norway* United Kingdom† USA‡ Australia§
HbA1c treatment target
Children/Type 1 < 18 years < 7.5% < 7%
Type 1 > 18 years < 7.5% < 7%
Type 2 6.5–7.5% < 7%
Younger (<80 years) < 7% < 7%
Older (>80 years) < 9% < 7%
Screening for diabetic retinopathy
First examination
Children/Type 1<18 years At age 12 years At puberty
< 30 years/Type 1 5 years after diagnosis At diagnosis 5 years after diagnosis At diagnosis
> 30 years/Type 2 At diagnosis At diagnosis At diagnosis At diagnosis
Follow-up in absence of retinopathy
Children/Type 1 < 18 years Annually Annually At least biannually
< 30 years/Type 1 Annually Annually Annually At least biannually
> 30 years/Type 2 Annually/Biannually Annually Annually At least biannually
Follow-up in retinopathy Individual Individual Individual Individual
Norwegian practice guidelines compared to practice guidelines in the United Kingdom, USA and Australia at the time (2005) of the study.
*The Norwegian College of General Practitioners, †National Institute for Clinical Excellence, ‡American Diabetes Association, §National Health and 
Medical Research CouncilBMC Health Services Research 2008, 8:159 http://www.biomedcentral.com/1472-6963/8/159
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smoking. In the questionnaire, regular examination was
defined as examination at regular intervals, e.g. yearly,
every six months or monthly. Furthermore, eye examina-
tion and vision examination was defined as examination
of the back of the eye/retina and examination of sight,
respectively. The specific questions on eye examination
were: "Do you have your eyes regularly examined due to
your diabetes?" and "In general, how long time is it
between the eye examinations?".
In 2001 a list system was implemented in Norwegian gen-
eral medical practice, implying that all citizens were listed
with one particular general practitioner (GP). In this sys-
tem the GP has the primary responsibility for the manage-
ment and follow-up of patients with diabetes. Referral to
a specialist (ophthalmologist) must be made by a GP. The
Norwegian College of General Practitioners guidelines
[26] were used as standard of patient care for comparison
with reported care (Table 1).
Data analysis was performed with the statistical package
SPSS version 13.0. Questionnaires with missing data for
gender, age or type of diabetes, or diabetes other than type
1 and type 2 (3%) were excluded from analysis. The data
were analysed in frequency and summation tables; group
differences were analysed using student-t, chi-square and
Fisher's exact tests. A p-value < 0.01 was considered statis-
tically significant. Features associated with known history
of diabetic retinopathy, visual symptoms, regular follow
up and lack of eye examination were analysed by univari-
ate and multiple logistic regression. Variables with p ≤
0.25 from the univariate analyses were entered into the
logistic regression models. Additionally, the prevalence
rate ratios (PR) were calculated for features associated
with regular eye examination and history of diabetic retin-
opathy to provide a natural intelligible effect measure and
to allow for comparison to the prevalence odds ratios
(POR).
Data were collected anonymously and the study was
approved by the Regional Committee for Medical
Research Ethics.
Results
The total number of responders was 1,396 (74%). Forty-
four questionnaires had missing information regarding
either age, gender, type of diabetes or diabetes other than
type 1 and type 2. The study is based on the remaining
1,352 cases, 699 (52%) were females. In all, 451 (33%)
responders had type 1 diabetes and 901 (67%) had type 2
diabetes. Table 2 shows basic demographic and medical
data of the responders.
In all, 1,141 (85%) of the responders had their eyes regu-
larly examined. Of these 1,052 (92%) were examined
according to recommended follow up schedule. Only 6%
reported never to have had their eyes examined. In per-
sons with type 1 diabetes, 88% (358/407) were examined
annually or more frequently: respectively 2%, 15%, 3%
and 69% were examined every 1–3 months, 4–6 months,
7–9 months and 10–12 months. In persons with type 2
diabetes, 98% (694/711) were examined biannually or
more frequently: respectively 2%, 13%, 1%, 63% and
18% were examined every 1–3 months, 4–6 months, 7–9
months, 10–12 months and 12–24 months. The time of
the first examination was in accordance to guidelines in
31% of responders with type 1 diabetes and in 47% of
responders with type 2 diabetes (Table 3). For all respond-
ers, the median interval between eye examinations was 12
months (65%). Eight-teen percent were regularly exam-
ined more frequently. In total, 1,169 (87%) responders
confirmed to have received some information about the
importance of having their eyes regularly examined due to
their diabetes. Responders who had their eyes examined
according to guidelines were more than twice as likely to
have received such information than responders who did
not undergo regular eye examinations (95% vs. 42%, p <
0.001). Having received information about the impor-
tance of eye examinations, and diabetes duration of more
than 10 years, were both independently associated with
regular eye examinations (Table 4).
Spectacles and/or contact lenses were used by 1,188
(88%) of the responders. The vision was regularly exam-
ined in 1,045 of the responders who used optical correc-
tion. This was significantly more frequent than among
responders who did not use optical correction (88% vs.
71%, p < 0.001). However, there was no significant differ-
ence in the frequency of eye examinations between the
groups. During the previous year, 611 (45%) of the
responders had experienced some kind of visual prob-
lems. Nearly two in five reported to be helped by optical
correction.
Visual problems due to diabetes were reported by 156
(12%) responders. A history of laser treatment of ocular
disease related to diabetes was reported by 81% of the
responders with visual problems related to diabetes and
known history of diabetic retinopathy. In all, 178 (13%)
reported a history of diabetic retinopathy, of these 101
(57%) also reported a history of laser treatment. Diabetic
retinopathy was associated with type 2 diabetes, diabetes
duration >10 years, use of oral anti-diabetic agents, use of
insulin, HbA1c above 7%, unstable blood glucose levels
and the use of anti-hypertensive medication. In a multi-
variate logistic regression analysis diabetes duration was
the only reported factor independently associated with a
history of diabetic retinopathy. The prevalence of diabetic
retinopathy was higher in patients with diabetes duration
longer than 10 years, than in patients with shorter diseaseBMC Health Services Research 2008, 8:159 http://www.biomedcentral.com/1472-6963/8/159
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duration prevalence ratio (95% CI) of 3.5 (2.5 to 5).
Moreover, a history of diabetic retinopathy was more fre-
quently reported by responders who had their eyes regu-
larly examined (Table 5).
Discussion
The vast majority of persons with diabetes responding to
this survey had their eyes examined according to guide-
lines advised by the Norwegian College of General Practi-
tioners [26], Table 1. Diabetes duration and having
received information about potential eye complications
were independently associated with eye care management
according to the guidelines.
Compared to cross-sectional surveys of the general dia-
betic population in UK, Australia and the United States
[27-30] the number of persons with diabetes who had
their eyes examined according to guidelines was equal or
higher in our study. Furthermore, the proportion who had
been examined according to guidelines (78%) were
noticeably higher than (53%) reported in a previous Nor-
wegian survey from 1996 [25]. Our study may reflect an
actual improvement in the management of ocular care in
Table 2: Demographic and medical characteristics of responders with type 1 and type 2 diabetes (n = 1,352), n (%)
All patients 
(n = 1,352)
Type 1 
(n = 451)
Type 2 
(n = 901)
Sex distribution
Female 699 (51.7) 247 (54.8) 452 (50.2)
Male 653 (48.3) 204 (45.2) 449 (49.8)
Age distribution*
< 20 years 7 (0.5) 6 (1.3) 1 (0.1)
21–30 years 55 (4.1) 54 (12.0) 1 (0.1)
31–40 years 108 (8.0) 87 (19.3) 21 (2.3)
41–50 years 185 (13.7) 106 (23.5) 79 (8.8)
51–60 years 315 (23.3) 91 (20.2) 224 (24.9)
61–70 years 349 (25.8) 71 (15.7) 278 (30.9)
71–80 years 261 (19.3) 30 (6.7) 231 (25.6)
81–90 years 72 (5.3) 6 (1.3) 66 (7.3)
Mean age (sd) 59 (± 15) 48 (± 15) 64 (± 11)
Mean duration of diabetes (sd)‡ 14 (± 12) 22 (± 14) 10 (± 9)
Mean HbA1c at last diabetes follow up (sd)§ 7.3 (± 1.2) 7.5 (± 1.0) 7.1 (± 1.3)
HbA1c within guideline treatment target*,§
All patients (HbA1c <7%/<9% depending on age) 461 (41.2) 107 (26.4) 354 (49.6)
Patients = 80 years (HbA1c <7%) 420 (39.1) 103 (25.6) 317 (47.2)
Patients > 80 years (HbA1c <9%) 41 (87.2) 4 (100) 37 (86.0)
Stable blood glucose level previous year&#x2225; 845 (63.9) 258 (58.6) 587 (66.6)
Diabetes treatment*
Diet (n = 757) 668 (88.2) 129 (66.2) 539 (95.9)
Exercise (n = 657) 536 (81.6) 112 (59.6) 424 (90.4)
Weight reduction (n = 430) 197 (45.8) 16 (10.4) 181 (65.6)
Oral medication (n = 771) 564 (73.2) 16 (10.3) 548 (89.1)
Insulin (n = 896) 742 (82.8) 443 (99.8) 299 (66.2)
Blood pressure and cholesterol medication*
Blood pressure (n = 1,337) 687 (51.4) 142 (31.6) 545 (61.4)
Cholesterol (n = 1,324) 591 (44.6) 123 (27.7) 468 (53.2)
Smoking
Present smoker† (n = 1,345) 203 (15.1) 88 (19.6) 115 (12.8)
Previous smoker (n = 1,306) 716 (54.8) 216 (50.2) 500 (57.1)
Known history of ocular disease
Cataract* (n = 1,019) 261 (25.6) 63 (17.2) 198 (30.4)
Diabetic retinopathy* (n = 1,058) 182 (17.2) 91 (23.3) 91 (13.6)
Glaucoma* (n = 905) 93 (10.3) 14 (4.2) 79 (13.8)
Age-related macula degeneration† (n = 857) 35 (4.1) 6 (1.9) 29 (5.4)
Hypertensive/occlusive vascular retinopathy (n = 851) 19 (2.2) 3 (0.9) 16 (3.0)
Laser treated diabetes related ocular disease¶
History of diabetic retinopathy reported 105 (10.0) 57 (14.7) 48 (7.2)
History of diabetic retinopathy not reported* 19 (1.8) 7 (1.8) 12 (1.8)
Pearson chi-square *p < 0.001 and †p < 0.01 between type 1 and type 2 diabetics.
Data missing for ‡31,§ 232, &#x2225;30 and ¶300 respondersBMC Health Services Research 2008, 8:159 http://www.biomedcentral.com/1472-6963/8/159
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people with diabetes in Norway. Improved eye care in
people with diabetes has also been reported in the United
States (1988–2002) and Australia (2003–2005) [28,31].
Unpublished data from a study undertaken in Norwegian
general practice in 1999/2000 revealed that three out of
four patients with diabetes were managed according to
current guidelines (Tor Claudi 2007, personal communi-
cation), indicating an improvement of care compared to
1996 [25]. The improved care could be explained by
increased focus on diabetes as a modern epidemic,
Table 3: Information about eye examination and frequency of eye and vision examination (n = 1,352), n (%)
All patients 
(n = 1,352)
Type 1
 (n = 451)
Type 2
 (n = 901)
Informed about the importance of eye examination*/‡,§ 1,169 (86.8) 433 (96.2) 736 (82.1)
Source of information not mutually exclusive*
General practitioner§ 678 (58.0) 205 (47.3) 473 (64.3)
Ophthalmologist 515 (44.1) 202 (46.7) 313 (42.5)
Hospital§ 338 (28.9) 224 (51.7) 114 (15.5)
Other medical practitioner§ 114 (9.8) 95 (21.9) 19 (2.6)
Optometrist 93 (8.0) 41 (9.5) 52 (7.1)
Leaflets/Journal of the Norwegian Diabetes Association&#x2225;,§ 298 (25.5) 136 (31.4) 162 (22.0)
Diabetes patient education course 218 (18.6) 77 (17.8) 218 (18.6)
Media 68 (5.8) 24 (5.5) 44 (6.0)
Other persons with diabetes§ 94 (8.0) 47 (10.9) 47 (6.4)
First eye examination after diagnosis†,§
Within 1 year 538 (40.3) 121 (26.9) 417 (47.1)
Within 1–5 years 433 (32.5) 138 (30.7) 295 (33.3)
After more than 5 years 221 (16.6) 140 (31.2) 81 (9.2)
Never examined 74 (5.5) 6 (1.3) 68 (7.7)
Unsure 68 (5.1) 44 (9.8) 24 (2.7)
Regular eye examination reported by one or more methods‡,§
Eye examination by one or more methods 1,141 (85.4) 416 (92.7) 725 (81.7)
Examination by ophthalmologist 965 (84.6) 339 (81.5) 626 (86.3)
Fundusphotography 443 (38.8) 202 (48.6) 241 (33.2)
Examination by optometrist 90 (7.9) 30 (7.2) 60 (8.3)
Examination by general practitioner 21 (1.8) 6 (1.4) 15 (2.1)
Regular vision examination reported by one or more methods
by one or more methods 1,161 (85.9) 386 (85.6) 775 (86.0)
by ophthalmologist 979 (84.3) 330 (85.5) 649 (83.7)
by optometrist 252 (21.7) 84 (21.8) 168 (21.7)
by other health care provider 33 (2.8) 18 (4.7) 15 (1.9)
by medical doctor 29 (2.5) 8 (2.1) 21 (2.7)
Missing data for *5,†18, ‡16 responders.
Pearson chi-square § p < 0.001 between type 1 and type 2 diabetics.
&#x2225; Journal of the Norwegian Diabetes Association
Table 4: Characteristics associated with regular eye examination in patients with diabetes
Characteristic 
(association)
Eye exam (%) in 
group with 
characteristic
Eye exam (%) in 
group without 
characteristic
Crude 
prevalence ratio 
(95% CI)
Crude odds 
ratio (95% CI)
Adjusted* odds 
ratio (95% CI)
P value*
Information on eye 
examination
93.0 29.7 3.1 (2.4 to 4.0) 31.5 
(20.7 to 48.1)
27.4 (16.7 to 44.8) <0.001
Diabetes duration > 
10 years
93.5 75.0 1.2 (1.2 to 1.3) 4.8 (3.4 to 6.8) 3.1 (2.0 to 5.1) <0.001
Visual problems 
related to diabetes
97.4 84.5 1.6 (1.1 to 1.2) 6.9 (2.5 to 19.1) 3.6 (1.2 to 10.6) 0.024
Using one or more 
optical corrections
85.9 81.5 1.1 (1.0 to 1.1) 1.4 (0.5 to 1.1) 1.5 (0.8 to 2.9) 0.234
Type of diabetes 
(Type 1)
92.7 81.7 1.1 (1.1 to 1.2) 0.3 (0.2 to 0.5) 0.9 (0.5 to 1.7) 0.842
*Multivariate logistic regression analysisBMC Health Services Research 2008, 8:159 http://www.biomedcentral.com/1472-6963/8/159
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increased professional knowledge about clinical guide-
lines, increased patient knowledge, and the coverage of
diabetes in mass media. However, the observation may
also to some extent reflect selection; the responders in our
study were members of the NDA and their rate of regular
eye examination is probably higher than in the general
diabetic population due to a higher interest in own health
and more exposure to patient education materials. More-
over, the overrepresentation of persons with type 1 diabe-
tes and persons with long term illness are probably other
important explanations for the high compliance with the
screening programme. Additionally, self-reports may
overestimate the frequency of eye examinations due to
recall bias, telescoping and social acceptance[32].
Utilization of eye care services is associated with the uses
of health services in general, and with health promotion
campaigns [27,29,31]. The fact that half of the patients
had not received information about the importance of
regular eye examinations by their GP and that not all
patients had their eyes examined according to practice
guidelines, suggest that there are still potentials for
improving the quality of care. Almost 90% of the respond-
ers in our study used some form of optical correction and
diabetic patients are frequently seen in Norwegian opto-
metric practice [33]. This suggests a role for optometrists
in promoting regular eye examinations in diabetes
patients. Moreover, the quality of ocular care can proba-
bly be improved by strengthening the optometrist-GP
communication ensuring that optometrists regularly
inform the GP about significant ocular findings (e.g. retin-
opathy in patients with diabetes) and also about patients
who are not regularly examined. This could be achieved
through continuing education of Norwegian optometrists
and professional awareness campaigns.
The prevalence of known history of diabetic retinopathy
among the responders corresponds with the total preva-
lence of diabetic retinopathy reported in a small Norwe-
gian community, the Eigersund study [4]. However, it is
lower than the reported prevalence in recent Danish stud-
ies [34,35]. On the other hand, the rate of responders with
a history of laser treatment of ocular complications due to
diabetes (three out of five) corresponds well with the fig-
ures in the Danish studies. The Danish studies are based
on clinical examination rather than on self-reports. If we
assume corresponding criteria for laser treatment in Nor-
way and Denmark, this suggests an underestimation of
the prevalence of diabetic retinopathy in our sample,
maybe due to lack of knowledge about the presence of
non-sight-threatening diabetic retinopathy among
responders.
Tight control of blood glucose and blood pressure reduces
the risk of progression towards sight threatening disease
[36] and visual outcome in patients with diabetes is
related to regular eye examination [22]. In our study, the
rate of established diabetic retinopathy was four times
higher in responders who had their eyes regularly exam-
ined as compared to those who did not attend regular eye
examinations. Among responders who had their eyes reg-
ularly examined, the frequency of retinopathy was nearly
twice as high among those who reported HbA1c values
above treatment target. In responders who did not have
their eyes regularly examined, however, the reported fre-
quency of retinopathy was the same for both patients with
HbA1c above and within treatment target. This further
adds to the assumption of a probable underestimation of
diabetic retinopathy in our population, not only due to
lack of patient knowledge, but also due to lack of regular
eye examinations.
The relatively high response rate implies that our findings
are representative for diabetes members of the NDA. An
important limitation is that the findings from this NDA
membership survey cannot be directly extrapolated to the
general diabetes population in Norway. The probable
underestimation of diabetic retinopathy prevalence even
in this patient group, may suggest that the underrecogni-
tion may be even larger in the general diabetes popula-
tion. However, we did not verify whether the reported eye
examination and medical history corresponded with
medical records.
Conclusion
The majority of diabetic members of NDA has their eyes
examined according to existing guidelines and are well
aware of the risk of vision loss due to diabetes. The
Table 5: History of diabetic retinopathy as reported by diabetic patients (n = 900) by blood glucose level* and eye examination, n (%)
Known history of diabetic retinopathy No history of diabetic retinopathy
Regular eye examination†
HbA1c within treatment target 39 (12.9) 264 (87.1)
HbA1c above treatment target 113 (23.3) 371 (76.7)
No regular eye examination
HbA1c within treatment target 3 (5.5) 52 (94.5)
HbA1c above treatment target 3 (5.3) 54 (94.7)
*HbA1c in accordance with treatment target level given in the Norwegian College of General Practitioners' guidelines.
† Pearson chi-square p = 0.001 between persons with HbA1c within and person with HbA1c above treatment target.BMC Health Services Research 2008, 8:159 http://www.biomedcentral.com/1472-6963/8/159
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reported prevalence of diabetic retinopathy is probably
underestimated due to lack of knowledge about estab-
lished retinopathy and undiagnosed diabetic retinopathy
among the responders indicating a potential for improve-
ment in care.
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